Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03463187 · ClinicalTrials.gov registry record · Phase 1

Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis

A Phase 1 study, sponsored by Jiangsu HengRui Medicine Co..

Completed
Registry status
Phase 1
Development phase
211
Enrollment target

NCT03463187: Completed Phase 1 study, sponsored by Jiangsu HengRui Medicine Co..

NCT03463187 is a Phase 1 study that has completed, run by Jiangsu HengRui Medicine Co.. The registered enrollment target is 211 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (252% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03463187, a Phase 1 study, has completed, sponsored by Jiangsu HengRui Medicine Co..

COMPLETED
Registry status
Phase 1
Development phase
211 participants
Enrollment target

Study Summary

This is a multi-regional, randomized, double-blind, placebo-controlled, clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of SHR-1314 in adults with moderate-to-severe plaque psoriasis.

Primary Outcome

Clinically significant events were defined as abnormal laboratory values and/or adverse events that are related to treatment

Interventions

  • DRUG Placebo
  • BIOLOGICAL SHR-1314

Trial Details

FieldValue
Enrollment Target 211 participants
Start Date 2017-12-15
Est. Completion 2020-08-31
Phase Phase 1
Jiangsu HengRui Medicine Co.

8 total trials

What the finished NCT03463187 record still lists

NCT03463187 is an interventional study that assigns participants to a tested intervention. The registered 211 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (252% higher).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT03463187 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03463187 about?

NCT03463187 is a clinical study titled "Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis". This is a multi-regional, randomized, double-blind, placebo-controlled, clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of SHR-1314 in adults with moderate-to-severe plaque psoriasis.

What is the current status of trial NCT03463187?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 211 participants. The study started on 2017-12-15. Estimated completion is 2020-08-31.

What interventions are being tested in trial NCT03463187?

The interventions under investigation include: Placebo (DRUG), SHR-1314 (BIOLOGICAL).

Who is sponsoring clinical trial NCT03463187?

This trial is sponsored by Jiangsu HengRui Medicine Co., which has 8 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03463187's enrollment target sits among peer trials

211 245th of 2000 higher than 1,756 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06698796 · 211 participants · Phase 3

    A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies

  • NCT04228978 · 212 participants · NA

    Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss

  • NCT04725721 · 212 participants · NA

    Testing FIRST in Youth Outpatient Psychotherapy

  • NCT06257576 · 212 participants · Phase 3

    Function of Tamsulosin in Older Males Undergoing Surgery with Indwelling Catheter

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03463187, the US trial registry maintained by the National Library of Medicine. NCT03463187 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.